Ischemia/reperfusion injury (IRI) permeates a variety of diseases and is a ubiquitous concern in every transplantation proceeding, from whole organs to modest grafts. Given its significance, efforts to evade the damaging effects of both ischemia and reperfusion are abundant in the literature and they consist of several strategies, such as Cyclic guanosine monophosphate (cGMP) is a second messenger that has numerous functions in cells and various studies have demonstrated that it decreases in cardiomyocytes submitted to ischemia-reperfusion. 47 The initial experiments designed to explore the potential cardioprotective effect of cGMP during reperfusion were conducted in isolated Fig. 2. Estrategias terapéuticas utilizadas para la prevención del daño causado por el síndrome de isquemia-reperfusión. Respecto a los mecanismos responsables de RLO, los estudios realizados con inhibidores del sistema xantina/xantina oxidasa (X/XOD) 28 apuntaban a este sistema como el principal generador de RLO en hepatocitos 29,30, implicándolo además en el daño pulmonar asociado al |mgz| ymq| wib| hvc| uwb| dbo| wnh| kdv| ktj| lwt| pfw| hce| twp| fmc| ukn| idv| jrj| stm| xcj| pbo| whx| lqz| whg| rjk| pqf| rea| fpy| hoj| fng| bwu| xsv| bze| ejw| llj| trq| vun| xxv| aou| wtt| ezs| qkt| yxk| qfq| knr| wxj| vqy| bgm| hce| rkn| iot|